Validation of a commercially available enzyme-linked immunoabsorbent assay for the quantification of human α-Synuclein in cerebrospinal fluid.
暂无分享,去创建一个
[1] K. Blennow,et al. Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study , 2015, Neurobiology of Aging.
[2] Tormod Fladby,et al. A Practical Guide to Immunoassay Method Validation , 2015, Front. Neurol..
[3] R. Kaji,et al. Reduced alpha‐synuclein in cerebrospinal fluid in synucleinopathies: Evidence from a meta‐analysis , 2014, Movement disorders : official journal of the Movement Disorder Society.
[4] N. Heegaard,et al. Cerebrospinal fluid α-synuclein in the differential diagnosis of parkinsonian syndromes , 2014 .
[5] Philip Scheltens,et al. Variability of CSF Alzheimer’s Disease Biomarkers: Implications for Clinical Practice , 2014, PloS one.
[6] Arthur W Toga,et al. Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. , 2013, JAMA neurology.
[7] M. Carrillo,et al. CSF biomarker variability in the Alzheimer's Association quality control program , 2013, Alzheimer's & Dementia.
[8] B. Mollenhauer,et al. Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects , 2013, Neuroscience Letters.
[9] J. Molinuevo,et al. Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. , 2012, Biomarkers in medicine.
[10] Brit Mollenhauer,et al. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study , 2011, The Lancet Neurology.
[11] B. Mollenhauer,et al. Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. , 2010, Biomarkers in medicine.
[12] M. Blankenstein,et al. Standardization of Assay Procedures for Analysis of the CSF Biomarkers Amyloid β (1-42), Tau, and Phosphorylated Tau in Alzheimer's Disease: Report of an International Workshop , 2010, International journal of Alzheimer's disease.
[13] B. Mollenhauer,et al. Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration , 2008, Experimental Neurology.
[14] R. Barbour,et al. Red Blood Cells Are the Major Source of Alpha-Synuclein in Blood , 2008, Neurodegenerative Diseases.
[15] Juan Manuel Maler,et al. Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid beta peptides. , 2006, Clinical chemistry.
[16] Viswanath Devanarayan,et al. Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement , 2006, Pharmaceutical Research.
[17] K. Yeo,et al. Lot-to-lot inconsistency of anticardiolipin reagents. , 2002, Clinical chemistry.